Future of Biotherapeutic Treatment for Bacterial Infections

Future of Biotherapeutic Treatment for Bacterial Infections

By Pharma Tech Outlook | Friday, January 04, 2019

Biopharmaceutical development is entering a new phase with advanced classes of treatments that are harnessing the natural power of viruses and cells and maneuvering them to fight human diseases. As the conventional therapies have not been able to provide efficient support for treatment, biotherapeutics offer a new and innovative method for the treatment of bacterial infections. Written below are two new technologies that have been making huge in-roads in the healthcare industry:

The Phage Therapy: The Phage therapy promises to be an intriguing approach in the fight against antibiotic resistance. Researchers across the globe are on a mission to hunt down naturally occurring Phage that can reduce the virulence of many deadly pathogens. Bacteria are good at evolving resistance to the phage attacks. Phage theories that use virulence factor or any antibiotic resistance can provide able support in the fight against deadly bacteria. The phage theory can give way to two possible results; one of them is that the phage will kill the bacteria that make the infection go away, and the other is that the bacteria develop a resistance to the phage but in the process loses its ability to cause an infection. Phage therapy is an easy process as phages are cheap to produce and the purification process is also easy. The physicians need to take the phage physically at the site of infection for an effective treatment. The next couple of years are going to be very crucial for Phage therapy treatment process.

Engineering Bacteria: Creating an inhospitable surrounding around the multi-drug resistant infection is another way of tackling the problem. Researchers are trying to harness synthetic biology by developing innovative tools and platforms as a means to create novel classes of therapeutics and diagnostics. The notion here is to engineer bacteria which functions as a living diagnostics and therapeutics. The researchers are using this approach to go after pathogens like Clostridium difficile, which are a leading cause of infectious diarrhea in hospitalized patients. The idea behind this treatment is to identify natural species that could be used to put infectious agents in check.

Check out: Top Biotech Companies

Weekly Brief

Read Also